Insights

Oncopeptides AB

Nasdaq Stockholm · LEI 549300J9WWQ5CBYQ1M77· Fiscal year 2025

Staff cost per employee
Not disclosed
Employees
Not disclosed

Quick read

  • Revenue grew 124.7% year over year.
  • Operating loss of $22.1M in 2025.

Last 3 years

Revenue
$3.1M2024$7.0M2025
Operating income
-$27.8M2024-$22.1M2025

See the share price on Google Finance ↗

Investor metrics

2025
Operating margin
-315.9%
Net margin
-350.9%
Equity ratio
-43.5%

USD at SEK 10.18 per $1 (2026-11-20, ExchangeRate-API)

Staff costs from the annual report (wages, social charges, pensions) divided by the average number of employees. Usually higher than take-home pay.

audited consolidated financial statements · View the annual report (filings.xbrl.org)

Not investment advice. Figures come from public filings and may contain errors.